Drug firms use legal loopholes to safeguard brand names

Gottlieb, Scott
August 2000
BMJ: British Medical Journal (International Edition);08/05/2000, Vol. 321 Issue 7257, p320
Academic Journal
Focuses on a report from the National Institute for Health Care Management on the efforts of United States pharmaceutical companies to extend the life of patents for lucrative drugs. How the extension of intellectual property protections prevents the entrance of inexpensive generic drugs into the market; Details of legal loopholes exploited by drug companies; Criticism of the report by the Pharmaceutical Research and Manufacturers of America.


Related Articles

  • Brand firms seek U.S. action on foreign pirates.  // Drug Topics;3/6/95, Vol. 139 Issue 5, p64 

    Reports on the PhRMA's call for crackdown on drug patent piracy in Argentina, Brazil, India, Singapore and Turkey.

  • GPIA opposes bill.  // Drug Topics;11/20/95, Vol. 139 Issue 22, p32 

    Reports that Generic Pharmaceutical Industry Association's (GPIA) opposition a House bill setting patent terms as the longer of 17 years from the date of issue. Move as a reward to patent holders for gaming the system through repeatedly filing continuation patent application.

  • Big Pharma's Bad Week in Washington. Mullin, Rick // Chemical Week;8/7/2002, Vol. 164 Issue 31, p30 

    Reports on the approval of the Greater Access to Affordable Pharmaceuticals bill aimed at closing loopholes in the 1984 Hatch-Waxman drug patent law in the U.S. Cancellation of a plan to provide prescription drug benefits under Medicare; Opposition of the Pharmaceutical Research and...

  • Pirates of patents. Conlan, Michael F. // Drug Topics;5/8/95, Vol. 139 Issue 9, p20 

    Reports on the publication of an advertisement in the `The Washington Post,' accusing Brazil of pharmaceutical patent piracy. Charges from the Pharmaceutical Research and Manufacturers Association; Cost to the United States of patent piracy by Brazil and Argentina.

  • GMiA demands patent review release.  // Australian Journal of Pharmacy;Aug2013, Vol. 94 Issue 1119, p8 

    The article reports that the Generic Medicines Industry Association (GMiA) has demanded the release of the Pharmaceutical Patent Review's report from the Australian government in 2013.

  • PhRMA's biggest challenge. Tosh, Mark // Medical Marketing & Media;Feb2004, Vol. 39 Issue 2, p6 

    Presents viewpoints concerning the difficulty in selecting qualified executive to lead the Pharmaceutical Research and Manufacturers of America (PhRMA) in Capitol Hill, Washingon D.C. Decision of Alan Holmer to retire as president and chief executive of PhRMA; Initiation of pediatric exclusivity...

  • Pharmaceuticals. Serb, Chris // H&HN: Hospitals & Health Networks;03/05/98, Vol. 72 Issue 5, p18 

    Presents information on plans to invest billions of dollars in a search for pharmaceuticals, by the Pharmaceutical Research and Manufacturers of America. Estimation of total sales; Information on the amount of money put into research and development (R&D); Contact information.

  • U.K. confidential. Gopal, Kevin // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p26 

    Focuses on the progress made by the pharmaceutical industry in the United Kingdom regarding the frontiers of information provided to people about medicines. Main proposals of the government's Freedom of Information white paper; Significance of the white paper to the industry and patients;...

  • NIHCM Report on Patent Protection Gets Negative Reception From PhRMA. Hess, Glenn // Chemical Market Reporter;07/31/2000, Vol. 258 Issue 5, p1 

    Focuses on the negative reaction of the Pharmaceutical Research and Manufacturers of America (PhRMA) on the report by the National Institute for Health Care Management Foundation on patent protection laws in the United States. Analysis of the report; Comments from PhRMA president, Alan F....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics